TGFB1 and cancer: High-throughput technologies, such as proteomics, scRNA-seq, and spatial transcriptomics (transcriptomic profiling of individual cells within their native tissue architecture), have begun to unravel our understanding of the role of FST in cancer as a potent inhibitor of the TGF-β pathway.